FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 258 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR How “the most advanced machine learning approach” is finding new cancer-causing... October 12, 2022 Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers April 26, 2023 NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... September 18, 2019 Load more HOT NEWS FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer Cancer in My Community: Working to Expand Access to Clinical Trials... Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... Her Massive Weight Loss Helped Her Feel A Lump In Her...
